Rouen, France, December 14, 2020 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has appointed Chantal Le Chat as an independent member of the Strategic Committee.

 

Chantal boasts 35 years of skill and know-how built up while working in a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including Global GM. Her duties as an independent member of the Strategic Committee will include supporting the governance of Robocath.

 

She will use her extensive knowledge of imaging systems to analyze strategic opportunities for promoting interoperability of equipment used in cath labs, in particular compatibility with R-One™, the first robotic platform, as well as future robotic generations.

 

Philippe Bencteux, President and founder of Robocath, said: “I’m honored that a leader in medical interventional imaging such as Chantal shares our vision for robot-controlled vascular operations. I’m excited to welcome her to the Strategic Committee. Her impressive experience will be key in advancing future developments at Robocath.”

 

Lucien Goffart, CEO of Robocath, added: “I’m also delighted that we’ve been able to boost our Strategic Committee by appointing Chantal. The sector is currently seeing significant changes, with the advent of new technologies that promise substantial added value. Robotics makes up a key part of this trend. New robotics projects will need to predict and embrace changes in the sector in order to ensure that they remain relevant in the market over the medium and long term. Chantal’s experience working for a leading imaging company will help us to quickly identify which technological development opportunities to focus on in order to speed up implementation and lock in growth.”

 

Chantal Le Chat, Independent Strategic Committee Member of Robocath, said: “I’m happy to be joining the Strategic Committee at Robocath. I’ve been following the company and its progress for a number of years and I’m especially impressed with the strides it has taken since being awarded CE marking in February 2019 for its first robot. The company is now right at the heart of a revolution in interventional medicine, which comes with a number of benefits for physicians, such as greater comfort and complete protection from X-rays, while the level of precision a robot can deliver is a boon for patients. Robocath’s commercial expansion is highly promising and, with its integration in the cath lab, the product should see significant growth. I’m looking forward to using my experience to help the company achieve its goals.”

 

Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRay tube division as well as the Vascular organization based in Buc (France) and Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming, in 2002, the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence and profitable growth. In 2005, Chantal was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation and introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-2014, she expanded her role to also cover the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the Ecole Supérieure de Physique et Chimie Industrielles (ESPCI) and a Master in Medical Instrumentations, Paris France – 1985.

  

About Robocath

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions.

R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs.

In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (Major adverse cardiovascular events).
R-One received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa.

Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen, France, Robocath has more than 40 employees.

www.robocath.com